Edward M. MD Kaye - Dec 3, 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Dec 3, 2025
Transactions value $
-$466,959
Form type
4
Date filed
12/5/2025, 08:50 PM
Previous filing
Dec 3, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kaye Edward M. MD Director C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 2025-12-05 0001522780

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise $0 +26.3K +51.16% $0.00 77.6K Dec 3, 2025 Direct
transaction STOK Common Stock Sale -$161K -5.22K -6.73% $30.76 72.3K Dec 4, 2025 Direct F1, F2
transaction STOK Common Stock Sale -$38.6K -1.23K -1.7% $31.32 71.1K Dec 4, 2025 Direct F1, F3
transaction STOK Common Stock Sale -$199K -6.37K -8.95% $31.33 64.7K Dec 5, 2025 Direct F1, F4
transaction STOK Common Stock Sale -$52.4K -1.68K -2.6% $31.15 63.1K Dec 5, 2025 Direct F5, F6
transaction STOK Common Stock Sale -$15.9K -500 -0.79% $31.85 62.6K Dec 5, 2025 Direct F5, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Performance Stock Units Options Exercise $0 -26.3K -100% $0.00 0 Dec 3, 2025 Common Stock 26.3K Direct F8, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive.
F5 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive.
F8 Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F9 Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.